Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease

EuroIntervention 2017;13:e248-e255 published online January 2017 published online e-edition June 2017. DOI: 10.4244/EIJ-D-16-00697

Christian Bradaric
Christian Bradaric1*, MD; Kristin Eser1, MD; Stephanie Preuss2, MD; Michael Dommasch1, MD; Isabell Wustrow1, MD; Nicolas Langwieser1, MD; Bernhard Haller3, PhD; Ilka Ott4, MD; Massimiliano Fusaro4, MD; Uwe Heemann2, MD; Karl-Ludwig Laugwitz1,5, MD; Adnan Kastrati4,5, MD; Tareq Ibrahim1, MD
1. Medizinische Klinik und Poliklinik, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; 2. Abteilung für Nephrologie, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; 3. Institut für Medizinische Statist

Aims: The aim of this study was to assess the impact of drug-eluting stents (DES) compared to bare metal stents (BMS) for the endovascular treatment of atherosclerotic renal artery stenos

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bare metal stentclinical researchhypertensionin-stent restenosisrenal artery stenosis
Interventions for hypertensionRenal artery angioplastyStents, devices and techniques
Read next article
How should I treat an unexpected deadlock at the time of transcatheter aortic valve prosthesis implantation?

Latest news